Dornase alfa
Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I, an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. It is produced in Chinese hamster ovary cells.
Medical uses
Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.A 2021 Cochrane systematic review found that dornase alfa probably improves lung function compared with placebo/no dornase alfa at multiple time points, while evidence for quality-of-life outcomes was limited. Rash and voice change were reported more frequently than with control, and serious adverse effects were not reported in the included trials.